AG
Andrew Gengos
Chief Financial Officer

Andrew Gengos insider trades: Terns Pharmaceuticals (TERN) stock buys and sales

Chief Financial Officer, Terns Pharmaceuticals Last trade Jun 27, 2025 25 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2013
7
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Andrew reports to the SEC

and 1 more company

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 27, 2025TERN↑ Buy$39K
Jun 16, 2025TERN↑ Buy$57K
Sep 5, 2024ATHA↓ Sell$720
Jun 7, 2023ATHA↑ Buy$51K
Jun 5, 2023ATHA↑ Buy$192K
Jan 5, 2023ATHA↓ Sell$4K
Nov 30, 2015IMUC↑ Buy$4K
Feb 18, 2015IMUC↑ Buy$25K
Aug 14, 2014IMUC↑ Buy$9K
Dec 18, 2013IMUC↑ Buy$19K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other TERN insiders

Open-market trades in the last 12 months

About Andrew Gengos's insider trades

Andrew Gengos is Chief Financial Officer at Terns Pharmaceuticals (TERN). Since Dec 18, 2013, Andrew has reported 8 open-market purchases worth $397K and 2 sales worth $4K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (15 filings), other transactions (2 filings), shares returned to the company (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TERN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.